(R)-1-methanesulfonyloxy-3-(4-methoxybenzyloxy)tetradecane | 288402-98-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-methanesulfonyloxy-3-(4-methoxybenzyloxy)tetradecane
• 英文别名: (R)-3-[(4-methoxybenzyl)oxy]tetradecyl methanesulfonate；(R)-3-(4-Methoxybenzyloxy)-1-methanesulfonyloxytetradecane；[(3R)-3-[(4-methoxyphenyl)methoxy]tetradecyl] methanesulfonate
• CAS: 288402-98-2
• 化学式: C₂₃H₄₀O₅S
• 分子量: 428.634
• InChiKey: NQVXQPQLRLPARR-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  29
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-1-methanesulfonyloxy-3-(4-methoxybenzyloxy)tetradecane 在 sodium hydroxide 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.25h， 生成 allyl 2-amino-2-deoxy-4,6-O-isopropylidene-3-O-[(R)-3-(4-methoxybenzyloxy)tetradecyl]-α-D-glucopyranoside
  参考文献：
  名称：

  具有醚链的脂质A型吡喃羧酸的合成及其生物学活性。

  摘要：

  描述了在C-3'和C-4位置均具有醚链的脂质A型吡喃羧酸的合成及其对人U937细胞的生物活性。

  DOI：

  10.1016/s0008-6215(01)00134-3
• 作为产物：
  描述：

  (R)-1,3-二羟基十四烷 在 二异丁基氢化铝 、 对甲苯磺酸 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (R)-1-methanesulfonyloxy-3-(4-methoxybenzyloxy)tetradecane
  参考文献：
  名称：

  具有醚链的脂质A型吡喃羧酸的合成及其生物学活性。

  摘要：

  描述了在C-3'和C-4位置均具有醚链的脂质A型吡喃羧酸的合成及其对人U937细胞的生物活性。

  DOI：

  10.1016/s0008-6215(01)00134-3

文献信息

• Ether type lipid a 1-carboxylic acid analogs
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20020161221A1

  公开（公告）日：2002-10-31

  A compound of formula (I) below, which exhibits excellent macrophage activity inhibitory action, is useful for the treatment or prophylaxis of inflammatory disorders, autoimmune diseases or septicemia. In a preferred embodiment, R 1 and R 3 each represents a C 1 -C 20 alkanoyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R 2 and R 4 each represents a C 1 -C 20 alkyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R 5 is a hydrogen atom, a halogen atom, a hydroxy group, or a C 1 -C 6 alkoxy group, and substituent group A is a halogen atom, a hydroxy group, an oxo group, a C 1 -C 20 alkoxy group, or a C 1 -C 20 alkanoyloxy group. 1

  以下为化合物式（I），该化合物表现出出色的巨噬细胞活性抑制作用，可用于治疗或预防炎症性疾病、自身免疫性疾病或败血症。在首选实施例中，R1和R3各代表一个C1-C20烷酰基团，该基团可以选择性地被一个或多个取代基团A所取代，R2和R4各代表一个C1-C20烷基团，该基团可以选择性地被一个或多个取代基团A所取代，R5是氢原子、卤素原子、羟基或C1-C6烷氧基团，取代基团A是卤素原子、羟基、氧代基、C1-C20烷氧基团或C1-C20烷酰氧基团。
• ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES
  申请人：Sankyo Company, Limited

  公开号：EP1152007A1

  公开（公告）日：2001-11-07

  A compound of formula (I), which exhibits excellent macrophage activity inhibitory action, is useful for the treatment or prophylaxis of inflammatory disorders. autoimmune diseases or septicemia. R1 and R3 each represents a C1-C20 alkanoyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R2 and R4 each represents a C1-C20 alkyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R5 is a hydrogen atom, a halogen atom, a hydroxy group, or a C1-C6 alkoxy group, and Substituent group A is a halogen atom, a hydroxy group, an oxo group, a C1-C20 alkoxy group, or a C1-C20 alkanoyloxy group.

  式（I）化合物具有出色的巨噬细胞活性抑制作用，可用于治疗或预防炎症性疾病、自身免疫性疾病或败血症。 R1 和 R3 各自代表 C1-C20 烷酰基，可任选被一个或多个选自取代基 A 的取代基取代、 R2 和 R4 各自代表一个 C1-C20 烷基，可任选被一个或多个选自取代基 A 的取代基取代、 R5 是氢原子、卤素原子、羟基或 C1-C6 烷氧基，取代基 A 是卤素原子、羟基、氧代基团、C1-C20 烷氧基或 C1-C20 烷酰氧基。
• Synthesis of lipid A analogues containing glucose instead of glucosamine and their LPS-antagonistic activities
  作者：Masao Shiozaki、Yukiko Watanabe、Yuji Iwano、Toshio Kaneko、Hiromi Doi、Daisuke Tanaka、Takaichi Shimozato、Shin-ichi Kurakata

  DOI：10.1016/j.tet.2005.03.034

  日期：2005.5

  Lipid A analogues containing glucose in substitution for glucosamine on the reducing end were synthesized, and the inhibitory activities on LPS-induced TNF alpha production (LPS-antagonistic activity) in vitro using human whole blood cells were measured. The IC50 values (nM) of these ten compounds, 8, 14, 21, 31, 40, 51, 57, 62, 67 and 72, were 11.2, 15.4, 2.7, 0.1, 0.4, 1.3, 3.2, 3.2, 1.4 and 14.4, respectively. And also inhibitory activities (ID50) on TNF alpha production toward galactosamine loaded C3H/HeN mice in vivo of compounds 21, 31, 57, 62 and 67 were measured. The values of these compounds were 0.29, 0.50, 0.61, not dose-dependent and 0.33 mg/kg, respectively. (c) 2005 Elsevier Ltd. All rights reserved.
• US6511965B2
  申请人：——

  公开号：US6511965B2

  公开（公告）日：2003-01-28
• Synthesis of lipid A type pyran carboxylic acids with ether chains and their biological activities
  作者：Yukiko Watanabe、Takashi Mochizuki、Masao Shiozaki、Saori Kanai、Shin-ichi Kurakata、Masahiro Nishijima

  DOI：10.1016/s0008-6215(01)00134-3

  日期：2001.7

  Synthesis of lipid A type pyran carboxylic acids having ether chains at both the C-3' and C-4 positions and their bioactivities toward human U937 cells are described.

  描述了在C-3'和C-4位置均具有醚链的脂质A型吡喃羧酸的合成及其对人U937细胞的生物活性。